• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

(CDK9-IN-8)

1

Identification

CDK9-IN-8 CDK9-IN-8
Name CDK9-IN-8
Formula C17H23ClN4O2S
MW 382.91
CAS No.
EINECS
Smiles S1C=C(C2C(Cl)=CN=C(NCCOC)C=2)N=C1NCC1CCOCC1
Synonyms Compound 13
InChI InChI=1S/C17H23ClN4O2S/c1-23-7-4-19-16-8-13(14(18)10-20-16)15-11-25-17(22-15)21-9-12-2-5-24-6-3-12/h8,10-12H,2-7,9H2,1H3,(H,19,20)(H,21,22)
2

Introduction

CDK9-IN-8 (Compound 13) is a highly selective and potent CDK9 kinase inhibitor with an IC50 of 1.04±0.012 μM. CDK9 is a key regulator of transcription elongation in eukaryotic cells and has been considered as a potential drug target for several diseases including cardiac hypertrophy and certain cancers such as a variety of blood cancers as well as solid tumors.

Background Information

3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance: EBNumber:EB100166982

Storage condition

Solubility

5

Mechanism and Indication

Signaling Pathways Cell Cycle/DNA Damage
Target CDK
Research Area Cancer
Indications
6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
7

Safety Data of CDK9-IN-8

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
AMEDCHEM CHINA
10

Related Products

Other Forms of

Name CAS No Formula MW

Recommended Compounds in CDK

Name CAS No Formula MW
LY2857785 1619903-54-6 C26H36N6O 448.6
THZ2 1604810-84-5 C31H28ClN7O2 566.0527
Palbociclib (isethionate) 827022-33-3 C26H35N7O6S 573.66
CDK9-IN-6 1391855-95-0 C27H37ClN6O2 513.07468
ML167 1285702-20-6 C19H17N3O3 335.36
AMG 925 1401033-86-0 C26H29N7O2 471.55
LDC000067 1073485-20-7 C18H18N4O3S 370.43
LEE011 (succinate hydrate) 1374639-79-8 C27H38N8O6X 570.64
LEE011 (succinate) 1374639-75-4 C27H36N8O5 552.63
LEE011 (hydrochloride) 1211443-80-9 C23H31ClN8O 471.0
LEE011 1211441-98-3 C23H30N8O 434.54
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 333.77
Wogonin 632-85-9 C16H12O5 284.26
1-NM-PP1 221244-14-0 C20H21N5 331.41
WHI-P180 211555-08-7 C16H15N3O3 297.31
THZ1 1604810-83-4 C31H28ClN7O2 566.05
Senexin A 1366002-50-7 C17H14N4 274.32
CDK4-IN-1 1256963-02-6 C22H29ClN8 440.97
Palbociclib (hydrochloride) 827022-32-2 C24H30ClN7O2 483.99
Purvalanol B 212844-54-7 C20H25ClN6O3 432.9

Recommended Compounds in Same Indication

Name CAS No Formula MW
11

Route of Synthesis

12

References

13

More Information

CDK9-IN-8

Tags: buy CDK9-IN-8 IC50 | CDK9-IN-8 price | CDK9-IN-8 cost | CDK9-IN-8 solubility | CDK9-IN-8 purchase | CDK9-IN-8 manufacturer | CDK9-IN-8 research buy | CDK9-IN-8 order | CDK9-IN-8 MSDS | CDK9-IN-8 chemical structure | CDK9-IN-8 Storage condition | CDK9-IN-8 molecular weight | CDK9-IN-8 mw | CDK9-IN-8 datasheet | CDK9-IN-8 supplier | CDK9-IN-8 cell line | CDK9-IN-8 NMR | CDK9-IN-8 MS | CDK9-IN-8 IR | CDK9-IN-8 solubility | CDK9-IN-8 Safe information | CDK9-IN-8 Qc and Spectral Information | CDK9-IN-8 Clinical Information | CDK9-IN-8 Clinical Trial | CDK9-IN-8 Route of Synthesis | CDK9-IN-8 storage condition | CDK9-IN-8 diseases and conditions | CDK9-IN-8 flash point | CDK9-IN-8 boiling point | CDK9-IN-8 melting point | CDK9-IN-8 storage condition | CDK9-IN-8 brand